rs1234032 - LINC02400 - GXYLT1
Magnitude 2.2 · 1 study on file
Reported associations
-
Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas - Unknown journal (n.d.) · Unknown authors · PubMed 34607834
ABSTRACT: OBJECTIVE Sulfonylureas, the first available drugs for the management of type 2 diabetes, remain widely prescribed today. However, there exists significant variability in glycemic response to treatment. We aimed to establish heritability of sulfonylurea response and identify genetic variants and interacting treatments associated with HbA1c reduction. RESEARCH DESIGN AND METHODS As an initiative of the Metformin Genetics Plus Consortium (MetGen Plus) and the DIabetes REsearCh on patient straTification (DIRECT) consortium, 5,485 White Europeans with type 2 diabetes treated with sulfonylureas were recruited from six referral centers in Europe and North America. We first estimated heritability using the generalized restricted maximum likelihood approach and then undertook genome-wide
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
rs1234032 C allele and sulfonylurea response before therapy initiation High
C allele carriers have 0.14% reduced HbA1c response to sulfonylureas due to increased GXYLT1 expression impairing Notch signaling and pancreatic beta cell development
Discuss rs1234032 status with physician; C allele carriers may benefit from alternative diabetes agents
- GWAS_CATALOG 34607834
Screening
-
monitor glucose response to sulfonylureas if C allele carrier Moderate
C allele carriers may not achieve adequate glycemic control on sulfonylureas; early response assessment enables timely therapeutic adjustment
Check HbA1c at 6-8 weeks after sulfonylurea start; if <0.5% reduction, consider alternative agent
- GWAS_CATALOG 34607834